Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats

BACKGROUND: Neratinib is a pan-ErbB tyrosine kinase inhibitor used for extended adjuvant treatment of HER2-positive breast cancer. Diarrhea is the main adverse event associated with neratinib treatment. We aimed here to determine whether antibiotic-induced gut microbial shifts altered development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Secombe, Kate R., Ball, Imogen A., Wignall, Anthony D., Bateman, Emma, Keefe, Dorothy M., Bowen, Joanne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111977/
https://www.ncbi.nlm.nih.gov/pubmed/35561424
http://dx.doi.org/10.1016/j.neo.2022.100806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111977/
https://www.ncbi.nlm.nih.gov/pubmed/35561424
http://dx.doi.org/10.1016/j.neo.2022.100806

Ejemplares similares